Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Immunodeficiencies

The viruses responsible for AIDS are human immunodeficiency virus 1 and 2 (HIV 1 and HIV 2) Both are retroviruses, meaning that their genetic material is RNA rather than DNA HI Vs require a host cell to reproduce and the hosts m humans are the T4 lymphocytes which are the cells primarily responsible for inducing the immune system to respond when provoked The HIV penetrates the cell wall of a T4 lymphocyte and deposits both its RNA and an enzyme called reverse transcriptase inside There the reverse transcriptase catalyzes the formation of a DNA strand that is complementary to the viral RNA The transcribed DNA then serves as the template from which the host lymphocyte produces copies of the virus which then leave the host to infect other T4 cells In the course of HIV reproduction the ability of the T4 lymphocyte to reproduce Itself IS compromised As the number of T4 cells decrease so does the body s ability to combat infections... [Pg.1179]

Inactivation and Removal of Viruses. In developing methods of plasma fractionation, the possibiHty of transmitting infection from human vimses present in the starting plasma pool has been recognized (4,5). Consequentiy, studies of product stabiHty encompass investigation of heat treatment of products in both solution (100) and dried (101) states to estabHsh vimcidal procedures that could be appHed to the final product. Salts of fatty acid anions, such as sodium caprylate [1984-06-17, and the acetyl derivative of the amino acid tryptophan, sodium acetyl-tryptophanate [87-32-17, are capable of stabilizing albumin solutions to 60°C for 10 hours (100) this procedure prevents the transmission of viral hepatitis (102,103). The degree of protein stabilization obtained (104) and the safety of the product in clinical practice have been confirmed (105,106). The procedure has also been shown to inactivate the human immunodeficiency vims (HIV) (107). [Pg.530]

Primary immunodeficiencies are uncommon, and may occur in 1 in 10,000 individuals (6). Many primary immunodeficiencies are hereditary and congenital, and first appear in infants and children. Primary immunodeficiencies are classified into four main groups (7) relating to the lymphocytes (B-ceUs, T-ceUs, or both), phagocytes, or the complement cascade (8). Primary deficiency diseases result from B-ceU defects in 50% of cases, from T-ceU defects in ca 10%, and from combined B- and T-ceU defects in ca 20%. Phagocytic disorders account for 18% and complement defects occur in 2% of all cases. [Pg.32]

Secondary immunodeficiencies (9) are much more common than primary ones and frequently occur as a result of immaturity of the immune system in premature infants, immunosuppressive therapy, or surgery and trauma. Illnesses, particularly when prolonged and serious, have been associated with secondary immunodeficiencies, some of which may be reversible. Acquked immune deficiency syndrome (AIDS) (10—12) may be considered a secondary immunodeficiency disease caused by the human immunodeficiency vimses HIV-1 or HIV-2. Hitherto unknown, the disease began to spread in the United States during the latter part of the 1970s. The agent responsible for this infection has been isolated and identified as a retrovims. [Pg.32]

The class III cytokine receptor family includes two TNE receptors, the low affinity NGE receptor and 7-ceU surface recognition sites that appear to play a role in proliferation, apoptosis, and immunodeficiency. TNE-a (- 17, 000 protein) is produced by astrocytes and microglia and can induce fever, induce slow-wave sleep, reduce feeding, stimulate prostaglandin synthesis, stimulate corticotrophin-releasing factor and prolactin secretion, and reduce thyroid hormone secretion. TNE-a stimulates IL-1 release, is cytotoxic to oligodendrocytes, and reduces myelination this has been impHcated in multiple sclerosis and encephalomyelitis. Astrocyte TNE-a receptors mediate effects on IL-6 expression and augment astrocytic expression of MHC in response to other stimulants such as lEN-y. [Pg.539]

The deterrnination of the presence of reverse transcriptase in vims-infected cells can be done using labeled nucleotide triphosphates. Reverse transcriptase is an enzyme capable of synthesizing DNA from RNA and it is thought to play an important role in vims-mediated cell modification. This enzyme is also a marker enzyme for HIV, the vims impHcated in causing acquired immunodeficiency syndrome (AIDS). The procedure utilizes radiolabeled nucleotides with nonlabeled substrates to synthesize tagged DNA. The degree of radioactive incorporation reflects the reverse transcriptase activity. [Pg.440]

Human Immunodeficiency Virus. Human immunodeficiency vims (HIV) causes Acquired Immunodeficiency Syndrome (AIDS), which has no cure. HIV infects the cells of the human immune system, such as T-lymphocytes, monocytes, and macrophages. After a long period of latency and persistent infection, it results in the progressive decline of the immune system, and leads to full-blown AIDS, resulting in death. [Pg.360]

Oxeta.nocins, Oxetanocia A (49), formerly oxetanocia, is the first naturally occurring oxetanose derivative and is isolated from Bacillus megaterium (1,145). It inhibits gram-positive bacteria, herpes vimses, and human immunodeficiency vims (HIV) (146). The chemical synthesis of (49) and several derivatives has been reported (147). [Pg.123]

The mechanism of inhibition has not been characterized, but it is probably related to the ionophoretic properties of these antibiotics. Monensin has been shown to inhibit the intracellular transport of viral membrane proteins of cells infected with Semliki Forest vims (169). The formation of syncytia, normally observed when T-lymphoblastoid cell line (CEM) cells are cocultivated with human immunodeficiency vims (HlV-l)-infected T-ceU leukemia cell line (MOLT-3) cells, was significantly inhibited in the presence of monensin (170). This observation suggests that the viral glycoproteins in the treated cells were not transported to the cell surface from the Golgi membrane. [Pg.172]

RNA-dependent DNA polymerase (reverse transcriptase) oncomavims, human immunodeficiency vims (HIV)... [Pg.302]

Another dideoxypyrimidine nucleoside active against human immunodeficiency vims is 3 -azido-2/3 -dideoxyuridine [84472-85-5] (AZDU or CS-87, 64) C H N O. Since its synthesis, (167) CS-87 has been identified as a promising antiHIV agent (168) and is currentiy undergoing phase I clinical trials in patients with AIDS and AIDS-related complex. It appears to be less potent than AZT against HIV in a peripheral blood mononuclear (PBM) cell screening system and in MT-4 cell lines. This lower activity in PBM cells appears to be related to a lower affinity of CS-87 for the enzyme responsible for its initial phosphorylation (169). However, CS-87 has significantly lower toxicity on bone marrow cells than AZT (170) and penetration of the CNS as a 5 -dihydropyridine derivative. [Pg.314]

In 1983 the move to develop red cell substitutes intensified when it was recognized that the acquired immune deficiency syndrome (AIDS) could be transmitted by the blood-bome human immunodeficiency vims (HIV). Concern for the nation s blood supply followed. Since that time other retrovimses have been identified, efforts to screen blood not only for these agents but also for vimses that cause hepatitis have intensified, the indications for transfusion have been reevaluated, and the use of blood products has become much more efficient. More carehil screening of donors, testing of all donated units, and a general awareness in the donor population have all contributed to a decreased risk from transfusion-contracted AIDS. [Pg.160]

Poly(ethylene glycol) (PEG) molecules attached to adenosine deaminase (ADA) have been used in patients exhibiting symptoms of the severe combined immunodeficiency syndrome (SCID) caused by ADA deficiency. The modified enzyme has a plasma half-life of weeks as compared to the unmodified enzyme (minutes) (248). PEG-L-asparaginase has induced remissions in patients with non-Hodgkin s lymphoma (248). However, one disadvantage of PEG-enzyme treatment is its expense, ie, a year s treatment costs about 60,000 (248). [Pg.312]

Rossmann, M.G. Antiviral agents targeted to interact with viral capsid proteins and a possible application to human immunodeficiency virus. Proc. Natl. Acad. Sci. USA, 85 4625-4627, 1988. [Pg.345]

Human immunodeficiency virus type 1 (infection with) (Vol. 67 1996)... [Pg.96]

ADA SCID (adenosine deaminase-defective severe combined immunodeficiency) is a fatal genetic disorder caused by defects in the gene that encodes adenosine deaminase (ADA). [Pg.420]

Hyland, L., et al., 1991. Human immunodeficiency viru.s-1 protea.se 1 Initial velocity. studies and kinetic characterization of reacdon intermediates by Isotope exchange. Biochemistry 30 8441-8453. [Pg.532]

Hyland, L., Toma.szek, T, and Meek, T, 1991. Human immunodeficiency viru.s-1 protease 2 Use of pH rate. studies and solvent isotope effects to elucidate details of chemical mechanism. Biochemistry 30 8454-8463. [Pg.532]


See other pages where Immunodeficiencies is mentioned: [Pg.484]    [Pg.484]    [Pg.484]    [Pg.142]    [Pg.122]    [Pg.236]    [Pg.32]    [Pg.32]    [Pg.33]    [Pg.33]    [Pg.34]    [Pg.476]    [Pg.499]    [Pg.102]    [Pg.304]    [Pg.313]    [Pg.313]    [Pg.314]    [Pg.315]    [Pg.123]    [Pg.311]    [Pg.328]    [Pg.319]    [Pg.205]    [Pg.420]    [Pg.522]    [Pg.524]    [Pg.532]    [Pg.570]   
See also in sourсe #XX -- [ Pg.146 ]

See also in sourсe #XX -- [ Pg.77 , Pg.86 , Pg.88 , Pg.89 , Pg.90 , Pg.91 ]

See also in sourсe #XX -- [ Pg.177 ]

See also in sourсe #XX -- [ Pg.788 ]

See also in sourсe #XX -- [ Pg.456 ]

See also in sourсe #XX -- [ Pg.5 , Pg.294 ]

See also in sourсe #XX -- [ Pg.383 ]

See also in sourсe #XX -- [ Pg.126 ]

See also in sourсe #XX -- [ Pg.56 ]

See also in sourсe #XX -- [ Pg.66 ]

See also in sourсe #XX -- [ Pg.297 ]




SEARCH



AIDS (acquired immunodeficiency

Acquired immunodeficiency

Acquired immunodeficiency disease

Acquired immunodeficiency disease virus

Acquired immunodeficiency syndrome

Acquired immunodeficiency syndrome AIDS)

Acquired immunodeficiency syndrome drug development

Acquired immunodeficiency syndrome drugs used

Acquired immunodeficiency syndrome epidemiology

Acquired immunodeficiency syndrome treatments

Acquired immunodeficiency syndrome vaccines

Acquired immunodeficiency syndrome virus infection

Acquired immunodeficiency syndrome, dementia

Acquired immunodeficiency virus

Activity against human immunodeficiency virus

Anti-AIDS drugs Acquired immunodeficiency syndrome

Anti-Human immunodeficiency virus

Anti-Human immunodeficiency virus HIV) activity

Anti-Human immunodeficiency virus of antiarone

Anti-Human immunodeficiency virus of broussoflavonol

Anti-Human immunodeficiency virus of gancaonin

Anti-Human immunodeficiency virus of glyasperin

Anti-Human immunodeficiency virus of licochalcone

Anti-Human immunodeficiency virus of mulberry tree

Anti-Human immunodeficiency virus of norartocarpetin

Anti-human immunodeficiency

Anti-human immunodeficiency effects

Anti-human immunodeficiency therapeutic agents

Anti-human immunodeficiency virus activity

Anti-human immunodeficiency virus agent

Antiviral agents immunodeficiency virus

Application to Viral and Immunodeficiency Diseases

Aquired immunodeficiency syndrome

Aspartic proteases immunodeficiency virus 1 protease

Castanospermine immunodeficiency virus

Dementia human immunodeficiency virus-related

Effects of Thymus Grafting in Human Primary Immunodeficiency Disorders

Enzyme inhibitors human immunodeficiency virus protease

Feline immunodeficiency virus

Future Anti-Human Immunodeficiency Virus Drugs Under Development

Gene therapy severe combined immunodeficiency

HIV (human immunodeficiency

Human Immunodeficiency Virus and Disease

Human Immunodeficiency Virus viral chemokines

Human Immunodeficiency viruse

Human immunodeficiency

Human immunodeficiency vims

Human immunodeficiency vims infection

Human immunodeficiency vims protease

Human immunodeficiency viral proteins

Human immunodeficiency viral proteins properties

Human immunodeficiency virus

Human immunodeficiency virus (HIV

Human immunodeficiency virus (HIV protease inhibitors

Human immunodeficiency virus (HIV vaccines

Human immunodeficiency virus , and

Human immunodeficiency virus -protease inhibitor

Human immunodeficiency virus Cytomegalovirus

Human immunodeficiency virus HAART

Human immunodeficiency virus HAART therapy

Human immunodeficiency virus HIV) infection

Human immunodeficiency virus abacavir

Human immunodeficiency virus about

Human immunodeficiency virus absorption, distribution, and

Human immunodeficiency virus action

Human immunodeficiency virus adverse effects

Human immunodeficiency virus amprenavir

Human immunodeficiency virus and AIDS

Human immunodeficiency virus assay

Human immunodeficiency virus atazanavir

Human immunodeficiency virus cells

Human immunodeficiency virus central nervous system expression

Human immunodeficiency virus chemistry

Human immunodeficiency virus chemokine coreceptors

Human immunodeficiency virus chemokine receptors

Human immunodeficiency virus cleavage sites

Human immunodeficiency virus combination therapy, AIDS

Human immunodeficiency virus complex infection

Human immunodeficiency virus compounds

Human immunodeficiency virus conformational changes

Human immunodeficiency virus cysteines

Human immunodeficiency virus delavirdine

Human immunodeficiency virus dendritic cells

Human immunodeficiency virus detection

Human immunodeficiency virus development

Human immunodeficiency virus development into AIDS

Human immunodeficiency virus discovery

Human immunodeficiency virus drug development

Human immunodeficiency virus drug resistance

Human immunodeficiency virus drug-resistant strains

Human immunodeficiency virus drugs targeting

Human immunodeficiency virus early phase

Human immunodeficiency virus efavirenz

Human immunodeficiency virus emtricitabine

Human immunodeficiency virus encephalitis

Human immunodeficiency virus encephalopathies

Human immunodeficiency virus enfuvirtide

Human immunodeficiency virus entry inhibitors

Human immunodeficiency virus enzyme inhibition

Human immunodeficiency virus evidence

Human immunodeficiency virus excretion

Human immunodeficiency virus flexibility

Human immunodeficiency virus hormone

Human immunodeficiency virus identification

Human immunodeficiency virus incidence

Human immunodeficiency virus indinavir

Human immunodeficiency virus infected cells

Human immunodeficiency virus infection

Human immunodeficiency virus infection development

Human immunodeficiency virus infection drug resistance

Human immunodeficiency virus infection immune system

Human immunodeficiency virus infection mechanisms

Human immunodeficiency virus infection resistance

Human immunodeficiency virus infection treatment

Human immunodeficiency virus infection, dementia

Human immunodeficiency virus influenza vaccine

Human immunodeficiency virus inhibition

Human immunodeficiency virus inhibitors

Human immunodeficiency virus initiation

Human immunodeficiency virus injuries

Human immunodeficiency virus interactions

Human immunodeficiency virus isolation

Human immunodeficiency virus lamivudine

Human immunodeficiency virus lopinavir

Human immunodeficiency virus lymph nodes

Human immunodeficiency virus mechanisms of action

Human immunodeficiency virus monocyte

Human immunodeficiency virus monocyte-derived macrophages

Human immunodeficiency virus mutation analysis

Human immunodeficiency virus nelfinavir

Human immunodeficiency virus neurocognitive impairment

Human immunodeficiency virus neurodegeneration

Human immunodeficiency virus neuropathy

Human immunodeficiency virus nevirapine

Human immunodeficiency virus nonnucleoside reverse

Human immunodeficiency virus opportunistic infections

Human immunodeficiency virus pathogenesis

Human immunodeficiency virus pharmacokinetics

Human immunodeficiency virus preparations

Human immunodeficiency virus principles

Human immunodeficiency virus progression

Human immunodeficiency virus protease

Human immunodeficiency virus protease design

Human immunodeficiency virus protease nonpeptidic

Human immunodeficiency virus protease peptidomimetic

Human immunodeficiency virus receptor

Human immunodeficiency virus replication

Human immunodeficiency virus resistance

Human immunodeficiency virus resistance mechanism

Human immunodeficiency virus resistance testing

Human immunodeficiency virus retrovirus

Human immunodeficiency virus reverse

Human immunodeficiency virus reverse inhibitor)

Human immunodeficiency virus reverse transcriptase

Human immunodeficiency virus reverse transcriptase HIV-RT)

Human immunodeficiency virus reverse transcriptase inhibitors

Human immunodeficiency virus ritonavir

Human immunodeficiency virus saquinavir

Human immunodeficiency virus specific agents

Human immunodeficiency virus specific tissues

Human immunodeficiency virus stavudine

Human immunodeficiency virus structure

Human immunodeficiency virus syndrome

Human immunodeficiency virus tenofovir

Human immunodeficiency virus therapeutic targets

Human immunodeficiency virus tipranavir

Human immunodeficiency virus transfer

Human immunodeficiency virus transmission

Human immunodeficiency virus treatment

Human immunodeficiency virus type

Human immunodeficiency virus type 1 (HIV

Human immunodeficiency virus type 1 integrase

Human immunodeficiency virus type 2, distribution

Human immunodeficiency virus type examples

Human immunodeficiency virus type isolation

Human immunodeficiency virus type members

Human immunodeficiency virus type probing

Human immunodeficiency virus type source

Human immunodeficiency virus types 1 and

Human immunodeficiency virus vaccines

Human immunodeficiency virus viral genome

Human immunodeficiency virus viral life cycle

Human immunodeficiency virus viral structure

Human immunodeficiency virus zidovudine

Human immunodeficiency virus, cytoplasmic

Human immunodeficiency virus, drugs active against

Human immunodeficiency virus-associated dementia

Human immunodeficiency virus-associated dementia chemokines

Human immunodeficiency virus. See

Human immunodeficiency viruses 1 and 2 (HIV

Immunodeficiency (severe

Immunodeficiency Agammaglobulinemia

Immunodeficiency diseases

Immunodeficiency disorders

Immunodeficiency states

Immunodeficiency syndrom

Immunodeficiency syndrom inhibitor

Immunodeficiency syndrome causative agent

Immunodeficiency syndromes

Immunodeficiency virus 1 (HIV

Immunodeficiency viruses

Immunodeficiency with dwarfism

Immunodeficiency, infectious disease

Immunodeficient

Immunodeficient

Infant human immunodeficiency virus infection

Interferon in human immunodeficiency virus-related dementia

Interleukin in human immunodeficiency virus-related dementia

Lentiviruses immunodeficiency virus

Mice, immunodeficient

Mononuclear phagocytes human immunodeficiency virus-infected

Murine acquired immunodeficiency

Murine acquired immunodeficiency syndrome

Phenotyping of human immunodeficiency virus

Primary immunodeficiencies

Proteinase, human immunodeficiency virus

Pseudohypericin against human immunodeficiency

Retroviruses immunodeficiency syndrom

Retroviruses immunodeficiency virus

SCIDS immunodeficiency syndrome

Severe combined immunodeficiency

Severe combined immunodeficiency SCID)

Severe combined immunodeficiency diseas

Severe combined immunodeficiency disease

Severe combined immunodeficiency mice

Severe combined immunodeficiency mice (SCID

Severe combined immunodeficiency syndrome

Severe combined immunodeficiency syndrome SCIDS)

Severe combined immunodeficiency syndrome gene therapy

Severe combined immunodeficient

Severe combined immunodeficient SCID)

Severe combined immunodeficient SCID) mice

Severe combined immunodeficient mouse model

Simian acquired immunodeficiency

Simian acquired immunodeficiency syndrome virus

Simian immunodeficiency

Simian immunodeficiency virus

Simian immunodeficiency virus (SIV

Simian-human immunodeficiency virus

Simian-human immunodeficiency virus SHIV)

Study Human Immunodeficiency Virus-1 Protease Inhibitors

Viruses human immunodeficiency virus

© 2024 chempedia.info